Studies have described that EGCG administrated intraperitoneally (20 mg/kg) daily for 60 days [123] decreased Aβ levels and plaque formation in the brain of APP/PS1 Tg mice via decreasing the expression of APP and Aβ in the hippocampus region, confirming the protective effect of EGCG in AD [124]. The gene discussed is APP; the disease is Alzheimer disease.